Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report

Table 1 Reports regarding the application of death protein-1/death-ligand 1 inhibitors in refractory or relapsed extranodal natural killer/T-cell lymphoma

Ref.	Number of cases	Age mean year (range)	Gender	Treatment	Stage	Response	OS or PFS
McGehee et al[16] 2021	1	72	1 M	Pembrolizumab plus RT	IV	CR	33 mo, alive
Du et al[17] 2020	3	52 (51-54)	3 M	PD-1 antibody, plus Chidamide, etoposide, and thalidomide	1 (33.3%) IV; 1 (33.3%) III; 1 (33.3%) II	2 (66.7%) CR; 1 (33.3%) PD	-
Kwong et al[18] 2017	7	49 (31-68)	7 M	Pembrolizumab	5 (71.4%) IV; 2 (28.6%) IE	5 (71.4%) C; 2 (28.6%) PR	-
Li et al[19] 2018	7	47 (17-61)	4 M; 3 F	Pembrolizumab	2 (28.6%) IV; 3 (42.9%) II; 1 (14.3%) IIIE; 1 (14.3%) IE	2 (28.6%) CR; 2 (28.6%) PR	5 mo OS; 4.8 mo PFS
Diab et al[20] 2021	1	82	M	Pembrolizumab	IV	CR	21 mo, alive
Lai et al[21] 2017	1	37	F	Pembrolizumab	IV	CR	-
Gao et al[22] 2020	41	48 (20-72)	27 M; 14 F	Sintilimab plus chidamide	26 (70.3%) IV; 15 (29.7%) Non-IV	16 (44.4%) CR; 5 (13.9%) PR	-
Kim et al[24] 2020	21	≤ 60 16; > 60 5	13 M; 8F	Avelumab	-	5 (23.8%) CR; 3 (14.3%) PR	-

OS: Overall survival; PFS: Progression-free survival; M: Male; F: Female; Non-IV: Non-stage IV patients; RT: Radiotherapy.